Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

Sanofi Shifts Focus: Consumer Health Stake Up for Grabs

by Team Lumida
October 11, 2024
in Health and Longevity, Markets
Reading Time: 3 mins read
A A
0
Sanofi Shifts Focus: Consumer Health Stake Up for Grabs
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com

Sanofi plans to sell a 50% stake in its consumer-health business to CD&R.

The consumer division, including Allegra and IcyHot, generated $5.7 billion last year.

Sanofi aims to focus on prescription drugs, mirroring industry peers.

What Happened?

Sanofi has entered negotiations to sell a controlling 50% stake in its consumer-health business to the private-equity firm Clayton Dubilier & Rice (CD&R). This division, known as Opella, reported sales of €5.18 billion ($5.67 billion) last year and employs over 11,000 people worldwide.

Sanofi’s decision aligns with its strategy to separate its consumer products, which include popular brands like Allegra, Dulcolax, and IcyHot, from its core prescription drugs and vaccines.

The company outlined this plan a year ago, joining industry giants like Johnson & Johnson, Pfizer, and GSK in moving away from over-the-counter products. Though financial terms are yet to be disclosed, media speculations suggest the consumer unit’s value could be around €15 billion.

Why It Matters?

This move marks a significant shift for Sanofi, emphasizing its commitment to focusing on more profitable and innovative prescription drugs. By divesting its consumer-health arm, Sanofi aims to hone its resources on developing cutting-edge medicines.

This decision mirrors a broader industry trend where major pharmaceutical companies are streamlining operations to concentrate on high-growth, high-risk sectors. For investors, this means a potential change in Sanofi’s risk profile and growth strategy.

As Sanofi transitions, it may also impact the competitive landscape in consumer health, with CD&R potentially driving new strategies for the acquired brands.

What’s Next?

Looking ahead, if the deal proceeds, you can expect Sanofi to intensify its focus on prescription drugs, possibly leading to increased investments in research and development.

The market will closely watch for any public listing of the consumer-health business, as previously suggested by Sanofi. For CD&R, acquiring a stake in such a substantial business offers a chance to expand its footprint in the consumer-health market.

Investors should monitor how this divestment affects Sanofi’s performance relative to its peers and any subsequent strategic moves by the company. As the transaction unfolds, it could serve as a bellwether for similar deals in the pharmaceutical sector.

Source: The Wall Street Journal
Tags: Consumer HealthSanofi
Previous Post

Crypto Firms Caught in $25 Million Market Manipulation

Next Post

Big Banks Set to Flood Market with Billions in Bonds

Recommended For You

Nasdaq 100 Futures Jump 2% and S&P 500 Futures 1.1% as Anthropic’s Above-Range IPO Revives the AI Trade After the S&P 500’s Fifth Straight Loss

by Team Lumida
10 hours ago

US stock futures jumped early Thursday as Anthropic’s $83 IPO pricing lifted AI sentiment, after the S&P 500 fell for a fifth straight session.

Read more

Hims & Hers Launches Five Compounded Peptide and Longevity Treatments on Its Peptides+ Platform After More Than 10,000 Sign Up in 15 Days

by Team Lumida
1 day ago

Hims & Hers began offering five compounded peptide and longevity treatments after HHS eased rules, while admitting there is more to learn on efficacy.

Read more

Dow Drops 426 Points as Nvidia’s Post-Earnings Bounce Fizzles, With CoreWeave Down 6%, Nebius 4% and Iren 3% as Neoclouds Reverse Early Gains

by Team Lumida
1 day ago

The Dow fell 426 points as Nvidia gave up its post-earnings gains, while CoreWeave, Nebius and Iren reversed early premarket jumps.

Read more

Wall Street Expects Global Earnings Growth to Halve to 16% in 2027 From 33.5%, With Goldman Seeing US Profit Growth Falling From 36% to 11% as AI Capex Growth Peaks in the First Half

by Team Lumida
1 day ago

Analysts expect MSCI ACWI earnings growth to slow to 16% in 2027 from 33.5%, and Goldman sees US profit growth falling to 11% from 36%, the FT reports.

Read more

Dow Falls 760 Points as Chip Stocks Slide Into Nvidia Earnings, With Micron Down 6% and Nvidia on Pace for Its Worst Month Since April 2022

by Team Lumida
2 days ago
BlackRock’s Larry Fink on Economic Growth and Market Misconceptions

The Dow fell 760 points as chipmakers slid ahead of Nvidia earnings, with Micron down about 6% and Nvidia off 26% this month.

Read more

Deutsche Bank Flagged $582 Million of Suspicious Epstein-Linked Payments in US Filings and Once Mistakenly Sent Out Trump’s Tax Statements, Leaked Documents Show

by Team Lumida
2 days ago

Leaked documents show Deutsche Bank filed US suspicious activity reports on $582 million of Epstein-linked transfers and once mistakenly sent Trump’s tax statements.

Read more

S&P 500 Sinks 1.92% and Nasdaq 2.49% for a Third Straight Loss as Nvidia Drops 4.1%, With Futures Mixed Hours Before Its Earnings

by Team Lumida
2 days ago

US stocks fell for a third day as Nvidia slid 4.1%, with the VIX jumping and futures mixed ahead of Nvidia’s results and retail sales data.

Read more

BlackRock Triples Its Equity Overweight to 3% and Broadens AI Bets in Its $300 Billion Model Portfolios, Pulling About $4.4 Billion From Its Treasury ETF

by Team Lumida
3 days ago
Is BlackRock the New Leader in Alternative Investments?

BlackRock lifted its equity overweight to 3% from 1% and broadened AI exposure in its $300 billion model portfolios, driving billions in ETF flows.

Read more

Nasdaq-100 Futures Drop 0.77% and SK Hynix Sinks 5.6% as Markets Brace for Nvidia’s First Post-Huang Earnings and Anthropic’s IPO

by Team Lumida
3 days ago
AI Bulls Trample Bond Market Warnings — S&P 500 Breaks 7,800 as Tech Rally Defies Elevated Yields, Fed Uncertainty, Global Tightening

US stock futures slipped and Asian chipmakers slid as investors braced for Nvidia's earnings and Anthropic's roughly $1.4 trillion IPO.

Read more

Nvidia’s 2031 Bond Yield Rises to 5.717% After Huang’s Exit, With $36 Billion of Neocloud Backstops Now Under Scrutiny

by Team Lumida
6 days ago

Nvidia’s 4.5% bond due 2031 yielded 5.717% on Friday, and analysts are questioning the company’s role in backing AI infrastructure after Jensen Huang’s exit.

Read more
Next Post
Big Banks Set to Flood Market with Billions in Bonds

Big Banks Set to Flood Market with Billions in Bonds

Record Deals but Shrinking Sizes: What’s Happening in Private Credit?

Record Deals but Shrinking Sizes: What’s Happening in Private Credit?

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

shallow focus photography of white bottle lot

FDA Approves Lilly’s Kisunla for Alzheimer’s

July 6, 2024
man with Uber eats backpack

Taiwan Blocks Uber’s $950M Foodpanda Acquisition on Competition Concerns

December 26, 2024
Bitcoin’s Hopes Dashed: China’s Stimulus Shortfall

Bitcoin Developer Proposes ‘Quantum Landmines’—Hidden Traps Force Thieves to Stake Collateral or Lose It

November 6, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018